Aadi bioscience announces financial results for the fourth quarter and full-year 2023 and provides corporate update

Fyarro® sales of $6.3 million for q4 2023 and $24.4 million for fy 2023 representing year-over-year growth of 21% and 60%, respectively registration-directed precision1 trial of nab-sirolimus in solid tumors with tsc1 or tsc2 inactivating alterations  on track to complete enrollment by may; two-thirds interim analysis planned for q3 2024 phase 2 trials in endometrial cancer and neuroendocrine tumors (nets) actively enrolling patients conference call to be held today at 8:30 am edt los angeles , march 13, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced financial results for the fourth quarter and full-year ended december 31, 2023, and highlighted recent corporate progress. "with strong execution against our commercial and development goals, 2023 was a year of progress and momentum for aadi," said dave lennon, president and ceo of aadi bioscience.
AADI Ratings Summary
AADI Quant Ranking